Anebulo Financial Statements From 2010 to 2024

ANEB Stock  USD 1.46  0.04  2.67%   
Anebulo Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Anebulo Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Anebulo Pharmaceuticals financial statements helps investors assess Anebulo Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Anebulo Pharmaceuticals' valuation are summarized below:
Market Capitalization
42.8 M
Earnings Share
(0.32)
We have found ninety-eight available fundamental signals for Anebulo Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Anebulo Pharmaceuticals prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 127 M. The current year's Enterprise Value is expected to grow to about 115.6 M
Check Anebulo Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anebulo Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 261.5 K, Depreciation And Amortization of 245.4 K or Interest Expense of 158.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 19.06. Anebulo financial statements analysis is a perfect complement when working with Anebulo Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Anebulo Pharmaceuticals Correlation against competitors.
For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.

Anebulo Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.9 M4.1 M5.8 M
Slightly volatile
Short and Long Term Debt Total161 K181.2 K197.3 K
Slightly volatile
Other Current Liabilities203.3 K104.2 K88.7 K
Slightly volatile
Total Current Liabilities390.1 K260.6 K278.5 K
Slightly volatile
Cash2.9 M3.1 M5.5 M
Slightly volatile
Cash And Short Term Investments2.9 M3.1 M5.5 M
Slightly volatile
Net Receivables2.8 K3.1 K3.4 K
Slightly volatile
Common Stock Total Equity19.4 K26.8 K15.8 K
Slightly volatile
Common Stock Shares Outstanding26.7 M25.8 M24.1 M
Slightly volatile
Liabilities And Stockholders Equity3.9 M4.1 M5.8 M
Slightly volatile
Non Current Liabilities Total98.9 K104.2 K2.1 M
Slightly volatile
Capital Surpluse1.2 K1.4 K1.5 K
Slightly volatile
Other Current Assets565.7 K413.8 K273.4 K
Slightly volatile
Other Stockholder Equity51.9 M69.2 M19.2 M
Slightly volatile
Total Liabilities247.6 K260.6 K2.3 M
Slightly volatile
Net Invested Capital3.6 M3.8 M2.9 M
Slightly volatile
Short and Long Term Debt161 K181.2 K197.3 K
Slightly volatile
Total Current Assets3.3 M3.5 M5.5 M
Slightly volatile
Capital Stock24.8 K25.9 K16.4 K
Slightly volatile
Net Working Capital3.1 M3.2 M4.7 M
Slightly volatile
Short Term Debt161 K181.2 K197.3 K
Slightly volatile
Common Stock24.3 K25.9 K16.2 K
Slightly volatile
Non Currrent Assets Other452.1 K508.6 K553.8 K
Slightly volatile

Anebulo Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income261.5 K249 K51.4 K
Slightly volatile
Depreciation And Amortization245.4 K258.3 K1.4 M
Pretty Stable
Selling General Administrative3.6 M4.8 M1.4 M
Slightly volatile
Selling And Marketing Expenses4.1 K4.3 K17 K
Slightly volatile
Other Operating Expenses6.8 M8.3 M2.6 M
Slightly volatile
Research Development3.2 M3.5 M1.3 M
Slightly volatile
Total Operating Expenses6.8 M8.3 M2.6 M
Slightly volatile
Net Interest Income94.9 K97.8 K34.2 K
Slightly volatile

Anebulo Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock6.2 M9.4 M4.7 M
Slightly volatile
Other Non Cash Items143.7 K151.2 K1.9 M
Pretty Stable
Change To Account Receivables2.8 K3.1 K3.4 K
Slightly volatile
Change To Operating Activities653.9 K1.2 M388.6 K
Slightly volatile
End Period Cash Flow2.9 M3.1 M5.5 M
Slightly volatile
Change To Netincome1.1 MM294.2 K
Slightly volatile
Stock Based Compensation639.2 K758.9 K330.9 K
Slightly volatile
Begin Period Cash Flow13.4 M11.2 M6.2 M
Slightly volatile
Dividends Paid6.6 M7.4 MM
Slightly volatile
Depreciation121 K136.1 K148.2 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables441.7 K345.5 K449.1 K
Slightly volatile
Cash Per Share0.110.11980.2289
Slightly volatile
Income Quality0.580.98650.7989
Slightly volatile
Current Ratio12.7913.462119.5781
Pretty Stable
Graham Number0.981.02720.7796
Slightly volatile
Interest Debt Per Share3.0E-44.0E-40.0058
Slightly volatile
Debt To Assets0.05320.05980.0651
Slightly volatile
Ebt Per Ebit0.940.98711.4912
Pretty Stable
Total Debt To Capitalization5.346.016.5429
Slightly volatile
Quick Ratio12.7913.462119.5781
Pretty Stable
Net Income Per E B T1.11.151.0167
Slightly volatile
Cash Ratio11.2811.874119.3611
Pretty Stable
Debt Ratio0.05320.05980.0651
Slightly volatile

Anebulo Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap127 M69.2 M148 M
Slightly volatile
Enterprise Value115.6 M66.1 M142.1 M
Slightly volatile

Anebulo Fundamental Market Drivers

Cash And Short Term Investments3.1 M

Anebulo Upcoming Events

9th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
18th of September 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of June 2023
Last Financial Announcement
View

About Anebulo Pharmaceuticals Financial Statements

Anebulo Pharmaceuticals stakeholders use historical fundamental indicators, such as Anebulo Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Anebulo Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Anebulo Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Anebulo Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Anebulo Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:
Check out the analysis of Anebulo Pharmaceuticals Correlation against competitors.
For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.32)
Return On Assets
(0.66)
Return On Equity
(1.14)
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.